Which has stronger valuation & earnings, ACHV or TRVI?

Trevi Therapeutics is trading at a lower price-to-earnings ratio than Achieve Life Sciences, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Achieve Life Sciences N/A N/A -$54.65M -$1.12 N/A Trevi Therapeutics N/A N/A -$42.76M -$0.34 N/A

Is ACHV or TRVI more profitable?

Trevi Therapeutics' return on equity of -23.59% beat Achieve Life Sciences' return on equity. Company Net Margins Return on Equity Return on Assets Achieve Life Sciences N/A -193.49% -111.88% Trevi Therapeutics N/A -23.59% -22.64%

Does the media prefer ACHV or TRVI?

In the previous week, Trevi Therapeutics had 9 more articles in the media than Achieve Life Sciences. MarketBeat recorded 10 mentions for Trevi Therapeutics and 1 mentions for Achieve Life Sciences. Trevi Therapeutics' average media sentiment score of 0.16 beat Achieve Life Sciences' score of 0.00 indicating that Trevi Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Achieve Life Sciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Trevi Therapeutics 3 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to BHC or ACHV?

In the previous week, Bausch Health Cos had 3 more articles in the media than Achieve Life Sciences. MarketBeat recorded 4 mentions for Bausch Health Cos and 1 mentions for Achieve Life Sciences. Bausch Health Cos' average media sentiment score of 1.08 beat Achieve Life Sciences' score of 0.00 indicating that Bausch Health Cos is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Bausch Health Cos 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Achieve Life Sciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer ACHV or HRMY?

In the previous week, Harmony Biosciences had 21 more articles in the media than Achieve Life Sciences. MarketBeat recorded 22 mentions for Harmony Biosciences and 1 mentions for Achieve Life Sciences. Harmony Biosciences' average media sentiment score of 0.85 beat Achieve Life Sciences' score of 0.00 indicating that Harmony Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Achieve Life Sciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Harmony Biosciences 8 Very Positive mention(s) 4 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better valuation and earnings, MLYS or ACHV?

Mineralys Therapeutics is trading at a lower price-to-earnings ratio than Achieve Life Sciences, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Mineralys Therapeutics N/A N/A -$154.65M -$2.05 N/A Achieve Life Sciences N/A N/A -$54.65M -$1.12 N/A

Is MLYS or ACHV more profitable?

Mineralys Therapeutics' return on equity of -27.92% beat Achieve Life Sciences' return on equity. Company Net Margins Return on Equity Return on Assets Mineralys Therapeutics N/A -27.92% -26.98% Achieve Life Sciences N/A -193.49% -111.88%

Does the media favor MLYS or ACHV?

In the previous week, Mineralys Therapeutics had 2 more articles in the media than Achieve Life Sciences. MarketBeat recorded 3 mentions for Mineralys Therapeutics and 1 mentions for Achieve Life Sciences. Mineralys Therapeutics' average media sentiment score of 0.93 beat Achieve Life Sciences' score of 0.00 indicating that Mineralys Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Mineralys Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Achieve Life Sciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Achieve Life Sciences (ACHV) Competitors

$6.69 +0.04 (+0.54%)

As of 12:23 PM Eastern

Compare

ACHV vs. TRVI, BHC, PBH, HRMY, and MLYS

Should you buy Achieve Life Sciences stock or one of its competitors? MarketBeat compares Achieve Life Sciences with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Achieve Life Sciences include Trevi Therapeutics (TRVI), Bausch Health Cos (BHC), Prestige Consumer Healthcare (PBH), Harmony Biosciences (HRMY), and Mineralys Therapeutics (MLYS). These companies are all part of the "pharmaceuticals" industry.

How does Achieve Life Sciences compare to Trevi Therapeutics?

Achieve Life Sciences (NASDAQ:ACHV) and Trevi Therapeutics (NASDAQ:TRVI) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, risk, media sentiment, profitability, valuation, dividends and earnings.

Trevi Therapeutics is trading at a lower price-to-earnings ratio than Achieve Life Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Achieve Life Sciences	N/A	N/A	-$54.65M	-$1.12	N/A
Trevi Therapeutics	N/A	N/A	-$42.76M	-$0.34	N/A

In the previous week, Trevi Therapeutics had 9 more articles in the media than Achieve Life Sciences. MarketBeat recorded 10 mentions for Trevi Therapeutics and 1 mentions for Achieve Life Sciences. Trevi Therapeutics' average media sentiment score of 0.16 beat Achieve Life Sciences' score of 0.00 indicating that Trevi Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Achieve Life Sciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Trevi Therapeutics	3 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Achieve Life Sciences presently has a consensus target price of $16.00, indicating a potential upside of 138.59%. Trevi Therapeutics has a consensus target price of $26.75, indicating a potential upside of 48.45%. Given Achieve Life Sciences' higher probable upside, analysts plainly believe Achieve Life Sciences is more favorable than Trevi Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Achieve Life Sciences	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	3.00
Trevi Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	3.00

Trevi Therapeutics' return on equity of -23.59% beat Achieve Life Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Achieve Life Sciences	N/A	-193.49%	-111.88%
Trevi Therapeutics	N/A	-23.59%	-22.64%

Achieve Life Sciences has a beta of 2.24, suggesting that its stock price is 124% more volatile than the broader market. Comparatively, Trevi Therapeutics has a beta of 1.03, suggesting that its stock price is 3% more volatile than the broader market.

33.5% of Achieve Life Sciences shares are owned by institutional investors. Comparatively, 95.8% of Trevi Therapeutics shares are owned by institutional investors. 1.8% of Achieve Life Sciences shares are owned by insiders. Comparatively, 15.4% of Trevi Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Trevi Therapeutics beats Achieve Life Sciences on 9 of the 12 factors compared between the two stocks.

How does Achieve Life Sciences compare to Bausch Health Cos?

Bausch Health Cos (NYSE:BHC) and Achieve Life Sciences (NASDAQ:ACHV) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, dividends, media sentiment, institutional ownership, valuation, risk, analyst recommendations and earnings.

In the previous week, Bausch Health Cos had 3 more articles in the media than Achieve Life Sciences. MarketBeat recorded 4 mentions for Bausch Health Cos and 1 mentions for Achieve Life Sciences. Bausch Health Cos' average media sentiment score of 1.08 beat Achieve Life Sciences' score of 0.00 indicating that Bausch Health Cos is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bausch Health Cos	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Achieve Life Sciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

78.7% of Bausch Health Cos shares are held by institutional investors. Comparatively, 33.5% of Achieve Life Sciences shares are held by institutional investors. 20.7% of Bausch Health Cos shares are held by company insiders. Comparatively, 1.8% of Achieve Life Sciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Achieve Life Sciences has a net margin of 0.00% compared to Bausch Health Cos' net margin of -10.12%. Achieve Life Sciences' return on equity of -193.49% beat Bausch Health Cos' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bausch Health Cos	-10.12%	-561.95%	6.31%
Achieve Life Sciences	N/A	-193.49%	-111.88%

Bausch Health Cos has a beta of 0.38, indicating that its stock price is 62% less volatile than the broader market. Comparatively, Achieve Life Sciences has a beta of 2.24, indicating that its stock price is 124% more volatile than the broader market.

Bausch Health Cos has higher revenue and earnings than Achieve Life Sciences. Achieve Life Sciences is trading at a lower price-to-earnings ratio than Bausch Health Cos, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bausch Health Cos	$10.27B	0.24	$157M	-$2.96	N/A
Achieve Life Sciences	N/A	N/A	-$54.65M	-$1.12	N/A

Bausch Health Cos presently has a consensus price target of $8.00, indicating a potential upside of 23.93%. Achieve Life Sciences has a consensus price target of $16.00, indicating a potential upside of 138.59%. Given Achieve Life Sciences' stronger consensus rating and higher possible upside, analysts plainly believe Achieve Life Sciences is more favorable than Bausch Health Cos.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bausch Health Cos	2 Sell rating(s)	5 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.71
Achieve Life Sciences	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	3.00

Summary

Bausch Health Cos and Achieve Life Sciences tied by winning 8 of the 16 factors compared between the two stocks.

How does Achieve Life Sciences compare to Prestige Consumer Healthcare?

Prestige Consumer Healthcare (NYSE:PBH) and Achieve Life Sciences (NASDAQ:ACHV) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, dividends, earnings, profitability, valuation, media sentiment, institutional ownership and analyst recommendations.

Prestige Consumer Healthcare has higher revenue and earnings than Achieve Life Sciences. Achieve Life Sciences is trading at a lower price-to-earnings ratio than Prestige Consumer Healthcare, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Prestige Consumer Healthcare	$1.10B	2.28	$190.30M	$3.57	14.92
Achieve Life Sciences	N/A	N/A	-$54.65M	-$1.12	N/A

Prestige Consumer Healthcare currently has a consensus target price of $70.75, indicating a potential upside of 32.79%. Achieve Life Sciences has a consensus target price of $16.00, indicating a potential upside of 138.59%. Given Achieve Life Sciences' stronger consensus rating and higher possible upside, analysts plainly believe Achieve Life Sciences is more favorable than Prestige Consumer Healthcare.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Prestige Consumer Healthcare	2 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.00
Achieve Life Sciences	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	3.00

In the previous week, Prestige Consumer Healthcare had 11 more articles in the media than Achieve Life Sciences. MarketBeat recorded 12 mentions for Prestige Consumer Healthcare and 1 mentions for Achieve Life Sciences. Prestige Consumer Healthcare's average media sentiment score of 0.79 beat Achieve Life Sciences' score of 0.00 indicating that Prestige Consumer Healthcare is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Prestige Consumer Healthcare	4 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Achieve Life Sciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Prestige Consumer Healthcare has a net margin of 15.57% compared to Achieve Life Sciences' net margin of 0.00%. Prestige Consumer Healthcare's return on equity of 11.39% beat Achieve Life Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Prestige Consumer Healthcare	15.57%	11.39%	5.66%
Achieve Life Sciences	N/A	-193.49%	-111.88%

99.9% of Prestige Consumer Healthcare shares are owned by institutional investors. Comparatively, 33.5% of Achieve Life Sciences shares are owned by institutional investors. 1.5% of Prestige Consumer Healthcare shares are owned by insiders. Comparatively, 1.8% of Achieve Life Sciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Prestige Consumer Healthcare has a beta of 0.34, suggesting that its share price is 66% less volatile than the broader market. Comparatively, Achieve Life Sciences has a beta of 2.24, suggesting that its share price is 124% more volatile than the broader market.

Summary

Prestige Consumer Healthcare beats Achieve Life Sciences on 10 of the 16 factors compared between the two stocks.

How does Achieve Life Sciences compare to Harmony Biosciences?

Achieve Life Sciences (NASDAQ:ACHV) and Harmony Biosciences (NASDAQ:HRMY) are both healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, media sentiment, dividends, institutional ownership and earnings.

Achieve Life Sciences has a beta of 2.24, indicating that its stock price is 124% more volatile than the broader market. Comparatively, Harmony Biosciences has a beta of 0.96, indicating that its stock price is 4% less volatile than the broader market.

Harmony Biosciences has higher revenue and earnings than Achieve Life Sciences. Achieve Life Sciences is trading at a lower price-to-earnings ratio than Harmony Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Achieve Life Sciences	N/A	N/A	-$54.65M	-$1.12	N/A
Harmony Biosciences	$868.45M	2.63	$158.69M	$3.08	12.71

In the previous week, Harmony Biosciences had 21 more articles in the media than Achieve Life Sciences. MarketBeat recorded 22 mentions for Harmony Biosciences and 1 mentions for Achieve Life Sciences. Harmony Biosciences' average media sentiment score of 0.85 beat Achieve Life Sciences' score of 0.00 indicating that Harmony Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Achieve Life Sciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Harmony Biosciences	8 Very Positive mention(s)	4 Positive mention(s)	8 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

33.5% of Achieve Life Sciences shares are owned by institutional investors. Comparatively, 86.2% of Harmony Biosciences shares are owned by institutional investors. 1.8% of Achieve Life Sciences shares are owned by company insiders. Comparatively, 11.0% of Harmony Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Harmony Biosciences has a net margin of 18.88% compared to Achieve Life Sciences' net margin of 0.00%. Harmony Biosciences' return on equity of 20.06% beat Achieve Life Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Achieve Life Sciences	N/A	-193.49%	-111.88%
Harmony Biosciences	18.88%	20.06%	14.15%

Achieve Life Sciences currently has a consensus price target of $16.00, suggesting a potential upside of 138.59%. Harmony Biosciences has a consensus price target of $45.50, suggesting a potential upside of 16.22%. Given Achieve Life Sciences' stronger consensus rating and higher probable upside, equities research analysts clearly believe Achieve Life Sciences is more favorable than Harmony Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Achieve Life Sciences	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	3.00
Harmony Biosciences	1 Sell rating(s)	4 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.50

Summary

Harmony Biosciences beats Achieve Life Sciences on 11 of the 15 factors compared between the two stocks.

How does Achieve Life Sciences compare to Mineralys Therapeutics?

Mineralys Therapeutics (NASDAQ:MLYS) and Achieve Life Sciences (NASDAQ:ACHV) are both healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, media sentiment, risk, analyst recommendations, earnings, institutional ownership, valuation and dividends.

Mineralys Therapeutics currently has a consensus target price of $49.33, suggesting a potential upside of 80.34%. Achieve Life Sciences has a consensus target price of $16.00, suggesting a potential upside of 138.59%. Given Achieve Life Sciences' stronger consensus rating and higher possible upside, analysts clearly believe Achieve Life Sciences is more favorable than Mineralys Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mineralys Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
Achieve Life Sciences	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	3.00

Mineralys Therapeutics has a beta of 0.68, indicating that its stock price is 32% less volatile than the broader market. Comparatively, Achieve Life Sciences has a beta of 2.24, indicating that its stock price is 124% more volatile than the broader market.

84.5% of Mineralys Therapeutics shares are held by institutional investors. Comparatively, 33.5% of Achieve Life Sciences shares are held by institutional investors. 18.9% of Mineralys Therapeutics shares are held by company insiders. Comparatively, 1.8% of Achieve Life Sciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

In the previous week, Mineralys Therapeutics had 2 more articles in the media than Achieve Life Sciences. MarketBeat recorded 3 mentions for Mineralys Therapeutics and 1 mentions for Achieve Life Sciences. Mineralys Therapeutics' average media sentiment score of 0.93 beat Achieve Life Sciences' score of 0.00 indicating that Mineralys Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Mineralys Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Achieve Life Sciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Mineralys Therapeutics' return on equity of -27.92% beat Achieve Life Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mineralys Therapeutics	N/A	-27.92%	-26.98%
Achieve Life Sciences	N/A	-193.49%	-111.88%

Mineralys Therapeutics is trading at a lower price-to-earnings ratio than Achieve Life Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mineralys Therapeutics	N/A	N/A	-$154.65M	-$2.05	N/A
Achieve Life Sciences	N/A	N/A	-$54.65M	-$1.12	N/A

Summary

Mineralys Therapeutics and Achieve Life Sciences tied by winning 7 of the 14 factors compared between the two stocks.

Get Achieve Life Sciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ACHV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ACHV vs. The Competition

Export

Metric	Achieve Life Sciences	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$689.88M	$11.88B	$7.03B	$12.96B
Dividend Yield	N/A	2.69%	2.58%	10.20%
P/E Ratio	-6.00	788.46	269.91	24.87
Price / Sales	N/A	969.81	654.69	108.21
Price / Cash	N/A	15.12	28.89	37.44
Price / Book	16.77	10.37	11.40	6.45
Net Income	-$54.65M	$2.77B	$3.45B	$347.50M
7 Day Performance	6.11%	2.26%	3.66%	3.77%
1 Month Performance	9.75%	-1.28%	-0.49%	-0.40%
1 Year Performance	168.24%	191.26%	77.51%	23.55%

Achieve Life Sciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ACHV Achieve Life Sciences	2.0558 of 5 stars	$6.69 +0.5%	$16.00 +139.3%	+166.0%	$689.36M	N/A	N/A	20
TRVI Trevi Therapeutics	3.3137 of 5 stars	$18.31 +2.3%	$24.91 +36.0%	+149.5%	$2.59B	N/A	N/A	20	Earnings Report Analyst Forecast
BHC Bausch Health Cos	3.0051 of 5 stars	$6.72 -4.1%	$8.00 +19.1%	+8.1%	$2.52B	$10.27B	N/A	20,300
PBH Prestige Consumer Healthcare	3.93 of 5 stars	$51.93 +0.0%	$70.75 +36.2%	-16.3%	$2.45B	$1.09B	13.23	540	Earnings Report
HRMY Harmony Biosciences	4.232 of 5 stars	$39.07 +9.7%	$42.63 +9.1%	+12.3%	$2.25B	$868.45M	15.69	200	Earnings Report Analyst Upgrade Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ACHV) was last updated on 8/10/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Achieve Life Sciences (ACHV) Competitors

ACHV vs. TRVI, BHC, PBH, HRMY, and MLYS

How does Achieve Life Sciences compare to Trevi Therapeutics?

Summary

How does Achieve Life Sciences compare to Bausch Health Cos?

Summary

How does Achieve Life Sciences compare to Prestige Consumer Healthcare?

Summary

How does Achieve Life Sciences compare to Harmony Biosciences?

Summary

How does Achieve Life Sciences compare to Mineralys Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ACHV vs. The Competition

Achieve Life Sciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Achieve Life Sciences (ACHV) Competitors

ACHV vs. TRVI, BHC, PBH, HRMY, and MLYS

How does Achieve Life Sciences compare to Trevi Therapeutics?

Which has stronger valuation & earnings, ACHV or TRVI?

Does the media prefer ACHV or TRVI?

Do analysts recommend ACHV or TRVI?

Is ACHV or TRVI more profitable?

Which has more risk and volatility, ACHV or TRVI?

Do institutionals & insiders have more ownership in ACHV or TRVI?

Summary

How does Achieve Life Sciences compare to Bausch Health Cos?

Does the media refer more to BHC or ACHV?

Do institutionals and insiders believe in BHC or ACHV?

Is BHC or ACHV more profitable?

Which has more risk & volatility, BHC or ACHV?

Which has preferable earnings and valuation, BHC or ACHV?

Do analysts recommend BHC or ACHV?

Summary

How does Achieve Life Sciences compare to Prestige Consumer Healthcare?

Which has preferable valuation & earnings, PBH or ACHV?

Do analysts rate PBH or ACHV?

Does the media refer more to PBH or ACHV?

Is PBH or ACHV more profitable?

Do insiders and institutionals believe in PBH or ACHV?

Which has more volatility and risk, PBH or ACHV?

Summary

How does Achieve Life Sciences compare to Harmony Biosciences?

Which has more volatility & risk, ACHV or HRMY?

Which has preferable earnings & valuation, ACHV or HRMY?

Does the media prefer ACHV or HRMY?

Do insiders and institutionals hold more shares of ACHV or HRMY?

Is ACHV or HRMY more profitable?

Do analysts recommend ACHV or HRMY?

Summary

How does Achieve Life Sciences compare to Mineralys Therapeutics?

Do analysts rate MLYS or ACHV?

Which has more risk & volatility, MLYS or ACHV?

Do institutionals & insiders hold more shares of MLYS or ACHV?

Does the media favor MLYS or ACHV?

Is MLYS or ACHV more profitable?

Which has better valuation and earnings, MLYS or ACHV?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ACHV vs. The Competition

Achieve Life Sciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools